|
RAB3GAP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.88640025611653E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.30040003396704E-09 |
| Normal-vs-Stage2 |
1.69350000001067E-06 |
| Normal-vs-Stage3 |
1.05709999642656E-08 |
| Normal-vs-Stage4 |
1.68930999999706E-05 |
| Stage1-vs-Stage2 |
6.276000E-01 |
| Stage1-vs-Stage3 |
3.984800E-01 |
| Stage1-vs-Stage4 |
8.508000E-01 |
| Stage2-vs-Stage3 |
8.994400E-01 |
| Stage2-vs-Stage4 |
8.186000E-01 |
| Stage3-vs-Stage4 |
6.900800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.60090005088642E-09 |
| Normal-vs-AfricanAmerican |
1.139900E-02 |
| Normal-vs-Asian |
7.69989999982457E-07 |
| Caucasian-vs-AfricanAmerican |
1.698180E-01 |
| Caucasian-vs-Asian |
7.783000E-01 |
| AfricanAmerican-vs-Asian |
1.456790E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.35359998157492E-09 |
| Normal-vs-Female |
5.41409994614384E-09 |
| Male-vs-Female |
3.264400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.45870000026294E-07 |
| Normal-vs-Age(41-60Yrs) |
2.54499976648503E-10 |
| Normal-vs-Age(61-80Yrs) |
1.33520000000775E-06 |
| Normal-vs-Age(81-100Yrs) |
2.298100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.740560E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.498600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.293600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.392600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.297400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.932400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.948180E-01 |
| Classical-VS-Follicular |
8.297500E-03 |
| Classical-VS-Other |
1.008040E-01 |
| Classical-VS-Normal |
4.5794000003152E-07 |
| Tall-VS-Follicular |
6.894400E-01 |
| Tall-VS-Other |
2.640000E-01 |
| Tall-VS-Normal |
4.11160000002297E-06 |
| Follicular-VS-Other |
4.152800E-01 |
| Follicular-VS-Normal |
9.22509957312911E-10 |
| Other-VS-Normal |
5.247600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.60650448078582E-11 |
| Normal-vs-N1 |
9.42130000014529E-07 |
| N0-vs-N1 |
6.600200E-01 |
|
|
